Table 3.

Correlations between OS and patient and tumor characteristics.

	Univariate analysis		P value	Multivariate analysis		P value
	Hazard ratio	95% CI		Hazard ratio	95% CI
Age (>59 years)	0.691	0.537–0.891	0.004	0.883	0.674–1.158	0.370
Sex (male)	1.090	0.836–1.420	0.525
Body mass index (<18.5 or >25 kg/m2)	1.168	0.879–1.552	0.285
ECOG PS score (>1)	0.951	0.671–1.349	0.780
Pathological differentiation (poorly)	1.409	1.062–1.868	0.017	1.268	0.952–1.688	0.105
The number of organs affected by metastasis (>1)	1.493	1.146–1.946	0.003	1.272	0.933–1.733	0.128
Peritoneal metastasis (Yes)	1.924	1.457–2.542	<0.001	1.558	1.106–2.196	0.011
TNM staging (IV)	1.338	0.982–1.822	0.065	0.945	0.668–1.337	0.749
CEA (>5 ng/mL)	1.240	0.960–1.602	0.099	1.284	0.956–1.723	0.097
CA19-9 (>37 U/mL)	1.196	0.922–1.550	0.178	1.215	0.925–1.596	0.161
CA72-4 (>6 U/mL)	1.278	0.993–1.645	0.057	1.034	0.789–1.356	0.808
Thrombocyte counts (>300 × 109/L)	1.164	0.891–1.520	0.267
ADR (≥41.64)	0.273	0.202–0.369	<0.001	0.317	0.231–0.437	<0.001

ADR, albumin to D-dimer ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; CEA, carcinoembryonic antigen; CA72-4, carbohydrate antigen 72-4; CA19-9, carbohydrate antigen 19-9; CI, confidence interval; OS, overall survival.